FilingReader Intelligence
Genscript Biotech expects $204m profit swing
July 21, 2025 at 11:19 PM UTC•By FilingReader AI
Genscript Biotech Corporation forecasts profit before tax of $175.4 million to $204.6 million for the six months ended June 30, 2025, versus a $127.9 million loss in the prior period.
The turnaround is primarily driven by license revenue of $182.2 million to $212.5 million, up from $755,000, mainly from LaNova Medicines Ltd.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:1548•Hong Kong Exchange
News Alerts
Get instant email alerts when Genscript Biotech Corp publishes news
Free account required • Unsubscribe anytime